We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Hits Suzhou Amerigen for Inadequate Investigations, Quality Controls
FDA Hits Suzhou Amerigen for Inadequate Investigations, Quality Controls
The FDA issued a Form 483 to drug manufacturer Amerigen for insufficient record-keeping and quality controls following a November 2016 inspection of the company’s Suzhou, China, facility.